ALK upgrades its full-year revenue outlook

Core Viewpoint - ALK has upgraded its full-year financial outlook for 2025 due to higher-than-expected revenue in Europe and an improved outlook for the remainder of the year [1][2]. Group 1: Financial Performance - Total revenue for Q2 grew by 12% in local currencies, reaching DKK 1,527 million, compared to DKK 1,374 million in the previous year [3]. - EBIT increased by 41% in local currencies to DKK 375 million, resulting in an EBIT margin of 25% [3]. - The revenue growth forecast has been revised to 12-14% in local currencies, up from the previous estimate of 9-13% [8]. Group 2: Market Dynamics - Q2 performance was positively influenced by sales of adrenaline autoinjectors and strong momentum for tablets in Europe, which is expected to continue in the second half of the year [2]. - There is anticipated solid growth in tablet sales in North America, contributing to the overall positive outlook [2]. - The updated forecast reflects reduced risks associated with market conditions in Europe for the remainder of the year [2]. Group 3: Strategic Investments - Based on the improved revenue outlook, ALK plans to allocate additional funds to strategic growth investments in the second half of the year [2].